**Central Nervous System (CNS) Agents: Multiple Sclerosis**

|  |  |
| --- | --- |
| Criteria 1 | NP- Bafiertam, Extavia, Glatiramer\*, Glatopa, Kesimpta, Mavenclad, Mayzent, Plegridy, Ponvory, Tascenso ODT, Teriflunomide\*, Vumerity, Zeposia  \*- Preferred product has BvG designation |

|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Central Nervous System (CNS) Agents: Multiple Sclerosis | | |
| **Criteria Subtitle** | Non-Preferred Products | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred | X | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code (s) | Type of Code (GCNSeqNo, HICL, NDC) |
| BAFIERTAM | 081120 | GCNSeqNo |
| EXTAVIA | 039483 | GCNSeqNo |
| EXTAVIA | 062602 | GCNSeqNo |
| GLATIRAMER | 050210 | GCNSeqNo |
| GLATIRAMER | 071942 | GCNSeqNo |
| GLATOPA | 050210 | GCNSeqNo |
| GLATOPA | 071942 | GCNSeqNo |
| KESIMPTA | 081415 | GCNSeqNo |
| MAVENCALD | 078079 | GCNSeqNo |
| MAYZENT | 079601 | GCNSeqNo |
| MAYZENT | 079602 | GCNSeqNo |
| MAYZENT | 079603 | GCNSeqNo |
| MAYZENT | 083188 | GCNSeqNo |
| MAYZENT | 083189 | GCNSeqNo |
| PLEGRIDY | 072674 | GCNSeqNo |
| PLEGRIDY | 072675 | GCNSeqNo |
| PLEGRIDY | 072680 | GCNSeqNo |
| PLEGRIDY | 072682 | GCNSeqNo |
| PLEGRIDY | 081976 | GCNSeqNo |
| PONVORY | 082092 | GCNSeqNo |
| PONVORY | 082093 | GCNSeqNo |
| TASCENSO ODT | 083636 | GCNSeqNo |
| TASCENSO ODT | 084181 | GCNSeqNo |
| TERIFLUNOMIDE | 069980 | GCNSeqNo |
| TERIFLUNOMIDE | 069979 | GCNSeqNo |
| VUMERITY | 080393 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0997 |  | Select and Free Text | Has the patient taken the drug in the previous 120 days?  If yes, please submit documentation of recent use. | Y | END (Pending Manual Review) |
| N | 0998 |
| 2 | 0998 |  | Select | Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)? | New Start (initial authorization request) | 0999 |
| Continuation (re-authorization request) | 1234 |
| 3 | 0999 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 1000 |
| N | 1235 |
| 4 | 1000 |  | Select and Free Text | Has the patient had an inadequate clinical response of at least 30 days with at least one preferred drug?  If yes, please submit the medication trials and dates. | Y | 1002 |
| N | 1001 |
| 5 | 1001 |  | Select and Free Text | Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?  If yes, please submit the medication name and reason for inability to use. | Y | 1002 |
| N | 1236 |
| 6 | 1002 |  | Select | Is the request for any of the following:  1) a nonsolid oral dosage formulation  2) a non-preferred extended release formulation  3) a non-preferred brand name that has a preferred generic product | Y | 1003 |
| N | 1004 |
| 7 | 1003 |  | Select and Free Text | Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)? | Y | 1004 |
| N | 1235 |
| 8 | 1004 |  | Select | Is the request for generic glatiramer, generic teriflunomide, or brand Mayzent? | Y | 1005 |
| N | END (Pending Manual Review) |
| 9 | 1005 |  | Select | What product is being requested? | Generic glatiramer | 1006 |
| Generic teriflunomide | 1006 |
| Brand Mayzent | 1007 |
| Other | 1235 |
| 10 | 1006 |  | Select and Free Text | Has the brand medication been attempted and failed or is the brand medication contraindicated?  If yes, please submit documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 11 | 1007 |  | Select and Free Text | Has the provider submitted documentation of genotype, liver function tests (LFTS), complete blood count (CBC), ophthalmic examination, varicella zoster virus antibodies, and electrocardiogram (ECG)? | Y | END (Pending Manual Review) |
| N | 1235 |
| 12 | 1234 |  | Select and Free Text | Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring? | Y | END (Pending Manual Review) |
| N | 1235 |
| 13 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |
| 14 | 1236 |  | Free Text | Please explain the reason(s) why the patient is unable to use medications not requiring prior approval. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: 365 Days

|  |  |
| --- | --- |
| **Last Approved** | 5/26/2023 |
| **Other** |  |